Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Sharell Cornett-Risher
Phone: 713.441.3250
This is an open-label, dose-escalation/dose-expansion study of INCB057643 in subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic a ... Read more >
Status: Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Sharell Cornett-Risher
Phone: 713.441.3250
This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone and in combination with various immunomodulatory agents in patients with relapsed/refractory multiple myeloma or patients with myeloma who have measureabl ... Read more >
Status: Open Not Enrolling
Investigator: Monisha Singh
Study Coordinator: Ashley Towne
Phone: 346.238.2006
This study is an open-label, multicenter, phase 1, dose escalation study of TAK-659 in adult patients with advanced solid tumor and lymphoma malignancies. This study will be the first to administer TAK-659 to humans. The patient population durin ... Read more >
Status: Enrolling
Investigator: Brian Bruckner
Study Coordinator: Deborah Barr
Phone: 713.441.3916
This study is evaluating the effectiveness of PleuraFlow System Active Clearance Technology (ACT) in the management of blood evacuation. The Pleuraflow System ACT is a guided wire with a distal loop that rests at the end of a chest tube. The sys ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Ashley Towne
Phone: 346.238.2006
Open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-typ ... Read more >
Status: Enrolling
Investigator: Jasleen Randhawa
Study Coordinator: Ashley Towne
Phone: 346.238.2006
Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine ... Read more >
Status: Open Not Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Erick Villarreal-Williams
Phone: 713.441.9775
A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients. Patients who started treatment with imatinib (Gleevec) when they were first diagnosed with CML, then switched to ... Read more >
Status: Open Not Enrolling
Investigator: Alpesh Shah
Study Coordinator: Patricia Brinegar
Phone: 713.441.3506
This is a prospective, multi-center, non-randomized, single arm clinical trial that will be conducted at up to 40 sites in the United States and OUS. A minimum of 40% of total patients will be enrolled in the US. This study will enroll patient ... Read more >
Status: Enrolling
Investigator: Alan Lumsden
Study Coordinator: Kim Donlon
Phone: 713.441.9394
This prospective, multicenter, single-arm clinical study will further evaluate the safety and effectiveness of Cook's permanent and retrievable inferior vena cava (IVC) filters (specifically, the Günther Tulip® Vena Cava Filter and Cook Celect® ... Read more >
Status: Active
Investigator: Swaminathan Iyer
Study Coordinator: Sharell Cornett-Risher
Phone: 713.441.3250
This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 monotherapy and R-907 (rituximab in combination with CUDC-907) in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Dif ... Read more >
